zyprexa documents ppt 1
Post on 09-Feb-2016
39 Views
Preview:
DESCRIPTION
TRANSCRIPT
Zyprexa documents ppt 1.
This powerpoint has a selection of pages from documents to do with
marketing issues.
What are the “Zyprexa Documents”• Class action court case v Eli-Lilly re alleged with-
holding of ADEs data (wght gain and diabetes) and off-label marketing (dementia and subsyndromal mood swings).
• Subpoenaed internal company documents.• Lawyer (Gottstein), public health physician expert
witness (Egilman), New York Times journalist (Berenson) December 2006.
• 358 files, copious data re int memos, powerpoint pres, marketing strategies…
• Website www.furiousseasons.com (Dawdy) and a German website.
• Judge ordered cannot be retrieved from internet.
What are the “Zyprexa Documents”
• Heavily downloaded from furiousseasons.com• Form basis of journalist articles and web-blog
analyses.• Paper for academic literature (Spielmans)
• Provide insight into the goals and functioning of a big pharmaceutical company.
Issues raised
• Marketing for “NCE’s” (New Clinical Entities) and off-label indications.– Alternatively described as “Disease Mongering” to
increase sales.• Damage control, use of “spin”, possible
concealment re ADEs.• Sophistication of pharma companies in
interacting with (controlling?) “customers”.= physicians, pharmacists, hospitals/govt, allied health,
patient advocacy groups.
ZY100035541 Olanzapine Lifeplan
• The “Safer Clozapine”• Market is
Schizophrenia.• No mention of bipolar
or dementia.
ZY100035541 Olanzapine Lifeplan
ZY100035541 Olanzapine Lifeplan
• The “Safer Clozapine”
• Market is Schizophrenia.
• No mention of bipolar or dementia.
ZY100035541 Olanzapine Lifeplan
ZY201548768 Betting the Farm
• Prozac patent due to expire August 2001.
ZY201548768 Betting the Farm
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY200270343 Zyprexa Product Team summary 1997
ZY100041262 PCP opportunity
ZY100041262 PCP opportunity
ZY100041262 PCP opportunity
ZY100520662 Zyprexa primary care briefing document 21July2000
ZY100520662 Zyprexa primary care briefing document 21July2000
ZY100520662 Zyprexa primary care briefing document 21July2000
ZY100520662 Zyprexa primary care briefing document 21July2000
ZY100520662 Zyprexa primary care briefing document 21July2000
ZY100582035 Zyprexa Complicated Mood Project date?
ZY201797499 email re driving depression story since 98 Feb 2000
ZY200083405 PCP vision
ZY200083405 PCP vision
ZY200083405 PCP vision
ZY200083405 PCP vision
ZY200083405 PCP vision
ZY100040886 Primary Care Physician strategy
ZY100040886 Primary Care Physician strategy
ZY100040886 Primary Care Physician strategy
ZY100040886 Primary Care Physician strategy
ZY200083622 Addressing PCP FAOC
ZY200083622 Addressing PCP FAOC
ZY200083622 Addressing PCP FAOC
ZY200083622 Addressing PCP FAOC
ZY 100175096Viva Zyprexa
ZY 100175096 Viva ZyprexaPCPs/GPs = financial opportunities
ZY 100175096 Viva ZyprexaUnmet needs/disease-mongering
ZY 100175096 Viva ZyprexaUnmet needs/disease-mongering
ZY 100175096 Viva ZyprexaUnmet needs/disease-mongering
ZY 100175096 Viva ZyprexaUnmet needs/disease-mongering
ZY 100175096 Viva ZyprexaIncentives to sales reps
ZY 100175096 Viva ZyprexaPhysician type casting & targeting
ZY 100175096 Viva ZyprexaPhysician CME strategy
ZY 100175096 Viva ZyprexaHave the “customers” got the message?
ZY 100175096 Viva Zyprexastudying and utilising the “customers”
ZY 100175096 Viva Zyprexa
To the tune of “Viva Las
Vegas”
top related